Search 

Northern Biotechnologies has raised $1.5M in round "a" private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, anti- viral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners.

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti-microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention

can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and anti- viral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets.

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of "green probiotic" cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies. 

Headquartered in Geneva, Switzerland, NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class pre-clinical and clinical drug candidates with a mix of both clinically validated and novel targets.

§  CHF 182M raised from high net worth individuals, private and corporate venture funds

§  In 2009, received the European Biotechnica Award

§  In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate

§  In 2011, received Orphan Drug designation in Europe and the USA for, and EUR 6 million FP7 grant from the European Commission for development of NI-0501 for HLH

§  In 2012, filing to initiate important clinical studies including the first Phase II study for NI-0501 in HLH, and first-in-man study for leading anti-TLR4 drug candidate, NI-0101

§  Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates

§  Potential to independently bring selected drugs to the market for focused applications

ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. 

Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration.   Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase1. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Two recent papers in NatureMedicine and CancerCELL stablished proof of concept data that support the use of LSD1 inhibitors in acute myeloid leukemia. Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in leukemia and the other in Huntington disease. Phase I/IIa studies are expected to start in early 2013.

In Oncology, we also develop new non invasive early diagnostics tools. Our first product GynEC®-DX consists on a new set of markers for triage in endometrial cancer from uterine aspirates.

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.

Sanifit offers a new approach for calcification disorders. Sanifit´s lead Product (SNF472) for the reduction of calcification in dialysis patients is entering Phase I clinical trials. For the dental field OTC products were developed and are being out-licensed. The international management team has proven track record and long industry experience. Sanifit operates from Switzerland and Spain

Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, is a leading worldwide provider of contract research services. Selcia operates two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products, (2) capillary electrophoresis-based fragment and natural product screening, (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies. 

SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline.

During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications:

SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma.

SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013.

SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013.

25 more repurposing programs per year are running to file the advanced company pipeline.

SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcγRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.

The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).

Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions.